Mural Oncology’s (MURA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Mural Oncology (NASDAQ:MURA) in a research note issued to investors on Monday,Benzinga reports. They currently have a $18.00 target price on the stock.

Separately, Raymond James started coverage on Mural Oncology in a research report on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price objective for the company.

Mural Oncology Stock Performance

Shares of NASDAQ MURA opened at $3.52 on Monday. Mural Oncology has a 1 year low of $2.88 and a 1 year high of $17.00. The stock has a fifty day moving average price of $3.38 and a two-hundred day moving average price of $3.38. The firm has a market cap of $59.98 million and a P/E ratio of -0.34.

Mural Oncology (NASDAQ:MURA) last released its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. On average, research analysts predict that Mural Oncology will post -7.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Adam D. Cutler sold 7,421 shares of the stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the sale, the chief financial officer now owns 71,438 shares in the company, valued at $243,603.58. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Institutional Trading of Mural Oncology

A number of hedge funds have recently made changes to their positions in MURA. BBR Partners LLC purchased a new stake in Mural Oncology in the 2nd quarter worth approximately $31,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology in the second quarter worth $34,000. Commerce Bank purchased a new stake in shares of Mural Oncology during the third quarter worth $39,000. FMR LLC boosted its position in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after purchasing an additional 11,423 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in Mural Oncology in the second quarter valued at about $70,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.